Introduction
Cough variant asthma (CVA) is a common phenotype of asthma characterized by chronic cough in the absence of typical wheezing or dyspnea and is recognized as an important cause of chronic cough across different age groups.1 Although CVA is often considered a milder or early form of classic asthma, some patients may progress to classic asthma, highlighting the importance of early recognition and timely treatment. The pathogenesis of CVA is multifactorial and has not been fully clarified. Current evidence suggests that airway inflammation, airway hyper-responsiveness, and neural dysregulation collectively contribute to the development of persistent cough.2 Immunologically, imbalances in T helper cell subsets, including Th1/Th2 and Th17/Treg axes, have been shown to play a central role in mediating airway inflammation and hypersensitivity.3 Epithelial barrier dysfunction, environmental exposure, and gene–environment interactions can further modulate disease susceptibility and progression.4 Despite advances in understanding these mechanisms, their translation into reliable diagnostic markers and individualized treatment strategies remains challenging.
From a diagnostic perspective, CVA remains difficult to define uniformly, and its clinical presentation often overlaps with other causes of chronic cough.1 Biomarkers such as fractional exhaled nitric oxide (FeNO) and small airway function indices (eg, MMEF) can assist in evaluation; however, their diagnostic performance remains variable, and they are best interpreted in combination with clinical features and bronchial provocation testing.5 Therefore, delayed or missed diagnosis remains a common issue in clinical practice. Current management strategies for CVA are largely based on asthma therapies, including inhaled corticosteroids and bronchodilators.6 Although these treatments are effective in many patients, a proportion of patients have incomplete symptom control, recurrence after treatment discontinuation, or concerns regarding long-term medication use. These limitations have encouraged further exploration of complementary and integrative approaches.
Traditional Chinese medicine (TCM) has been widely used for the management of chronic respiratory diseases, including CVA.7 Notably, CVA exhibits substantial inter-patient heterogeneity in inflammatory phenotypes, triggering factors, and clinical manifestations. Conceptually, this complexity aligns well with the core principle of TCM syndrome-differentiated individualized therapy, which tailors interventions according to each patient’s unique pathological pattern. This theoretical match provides an important rationale for applying TCM in CVA intervention.
Within the TCM theoretical framework, CVA is associated with dysfunction of the lung, spleen, and kidney systems, together with wind-related triggers, phlegm retention, and blood stasis.7 Its treatment is guided by syndrome differentiation, emphasizing individualized therapy that aims to relieve cough symptoms and regulate the patient’s underlying syndrome pattern. In addition, emerging experimental and clinical studies suggest that TCM interventions may modulate immune responses, suppress inflammatory signaling pathways, and influence the gut–lung axis.8 [Note: Reference8 will be replaced with a recent asthma/CVA-specific gut-lung-axis reference in the final revised manuscript.] However, the existing evidence remains heterogeneous, and further well-designed clinical and mechanistic studies are needed to clarify the efficacy and biological basis of TCM in CVA.
The specific aims of this review are to synthesize contemporary knowledge regarding CVA and systematically evaluate the theoretical basis, mechanistic evidence, and clinical performance of TCM for CVA. This manuscript is structured as follows: first, we summarize the epidemiology, diagnostic dilemmas, genetic susceptibility, and pathophysiological features of CVA; second, we interpret TCM theoretical understanding of CVA and review available pre-clinical mechanistic findings; third, we appraise current clinical evidence for TCM interventions; finally, we discuss major limitations within the existing literature and outline priority directions for future research toward better integration of TCM and modern respiratory medicine.
Epidemiology
The reported proportion of CVA among patients with chronic cough varies across regions. A Korean study of patients with chronic cough showed that CVA accounted for 40.8% of chronic cough etiologies, which was higher than the proportions attributed to gastroesophageal reflux disease (GERD) and upper airway cough syndrome (UACS).9 Multicenter studies in China have shown that CVA accounts for approximately 25–30% of chronic cough etiologies, with a slightly higher reported proportion in southern regions such as Guangzhou than in northern regions.10 In a Japanese study, CVA accounted for 42.2% of chronic cough etiologies and was reported as the most common cause.11
Environmental exposure may contribute to the occurrence and aggravation of CVA symptoms (Figure 1). A study of Chinese children showed that PM2.5 concentration was positively associated with CVA occurrence, with a higher frequency of CVA observed when PM2.5 concentrations were >75 μg/m3 than when they were <35 μg/m3.12 Seasonal variation was also reported, with a higher occurrence of CVA in spring, when PM2.5 concentrations were relatively elevated.12 Experimental evidence further supports the role of air pollution in cough hypersensitivity and airway inflammation. In a guinea pig model, 14 days of traffic-related air pollution (TRAP) exposure increased citric acid-induced cough responses approximately fourfold, while the eosinophil proportion in bronchoalveolar lavage fluid (BALF) increased to approximately 30%.13Figure 1Epidemiological burden and risk factors of CVA.
Research reports from different regions indicate that CVA accounts for approximately 25% −42% of the causes of chronic cough. Specifically, China accounts for approximately 25% −30%, South Korea for 40.8%, and Japan for 42.2%. Risk factors for CVA are grouped into three domains: genetic susceptibility (variants at the GSDMB/ORMDL3, LPCAT1, IL4R, and IL6 loci), environmental exposure (PM2.5 > 75 μg/m3, spring season, and TRAP), and population characteristics (female predominance, postmenopausal status, middle age [30–50 years], and occupational exposure).A two-part infographic summarizes cough-variant asthma (CVA).
On the left, a Disease burden panel lists three country boxes with percentages: China 25 to 30 percent, Korea 40.8 percent and Japan 42.2 percent. On the right, a circular wheel labeled Risk factors is split into three colored wedges. The green wedge (genetic susceptibility) shows a DNA icon and gene names GSDMB/ORMDL3, LPCAT1, IL4R and IL6.
The yellow wedge (environmental exposure) includes icons of factories/smog and traffic, with items PM2.5 greater than 75 microg/m superscript 3, spring and TRAP. The orange wedge (population characteristics) lists: female greater than male, postmenopausal, middle-aged (30 to 50 years) and occupational exposure.Infographic linking cough-variant asthma to genes, air pollution/season and demographic traits.Abbreviations: CVA, cough variant asthma; GSDMB, gasdermin B; ORMDL3, orosomucoid-like 3; LPCAT1, lysophosphatidylcholine acyltransferase 1; IL4R, interleukin-4 receptor; IL6, interleukin-6; PM2.5, fine particulate matter with an aerodynamic diameter ≤ 2.5 μm; TRAP, traffic-related air pollution.
CVA appears to occur more frequently in middle-aged adults, with some studies reporting sex-related differences. A Chinese study reported a mean age of 43.0 ± 13.7 years, with 67.2% of patients aged 30–50 years, and a slightly higher proportion of women than men.14 A Korean study also reported a higher proportion of women among patients with CVA, and the mean age was higher in women than in men.9
Age- and sex-related differences may be associated with hormonal status and cough reflex sensitivity. A study of women with CVA showed that sputum eosinophil proportions and FeNO levels were higher in postmenopausal women than in premenopausal women.14 In addition, capsaicin cough thresholds were lower in women with CVA than in men, suggesting greater cough reflex sensitivity in women.14 Sex-related differences in CVA may also be biologically linked to hormonal effects on asthmatic airways. Recent reviews of asthma and allergic diseases indicate that estrogen can enhance type 2 immune responses, increase eosinophilic inflammation, and upregulate interleukin (IL)-4 and IL-13 signaling, thereby contributing to greater airway hyperresponsiveness in women.15,16 However, direct mechanistic evidence specific to CVA remains limited, and most current data are extrapolated from the broader asthma literature.
Occupational exposure may contribute to CVA onset or symptom aggravation in susceptible individuals. In a case report, a 33-year-old female healthcare worker experienced worsening CVA symptoms and an 11% reduction in FEV1 on pulmonary function testing after repeated exposure to thiols in skunk spray.17 In addition, Korean cough guidelines indicate that occupational exposure to allergens, dust, or chemicals should be considered during the evaluation of chronic cough and asthma-related cough.18
Diagnosis
The diagnosis of CVA remains challenging because chronic cough may be the sole presenting symptom, and objective test results are not always consistently abnormal. Recent evidence indicates that CVA is frequently under-recognized because of delayed clinical suspicion and limitations of diagnostic testing.1 In practice, diagnosis should be based on chronic cough as the predominant symptom, together with objective evidence supporting asthma, such as variable airflow limitation or airway hyperresponsiveness (Figure 2). Consistent with the 2022 European Respiratory Society guidelines for adult asthma diagnosis, spirometry is the preferred initial test, followed, when necessary, by bronchodilator reversibility testing, exhaled nitric oxide, peak expiratory flow variability, or bronchial challenge testing.19 The 2020 ERS chronic cough guidelines recognize CVA as an important treatable trait among patients with chronic cough.20 Clinically, patients with CVA most commonly present with dry, nocturnal, and cold-induced cough.21 Pulmonary function testing typically shows that FEV1/FVC is lower than that in healthy individuals but generally higher than that in patients with classic asthma.22 Bronchial provocation testing remains an important objective test for confirming airway hyperresponsiveness in suspected CVA.
In a cohort of patients with chronic cough, bronchial hyperresponsiveness demonstrated a positive predictive value of 90.9% for CVA.23Figure 2Stepwise diagnostic pathway for cough variant asthma. In patients presenting predominantly with chronic cough, evaluation begins with characteristic symptoms, red flags, and common alternative diagnoses, followed by spirometry and bronchodilator testing when appropriate. If initial testing is inconclusive, FeNO, PEF variability, or bronchial challenge testing may be used selectively to provide objective evidence of variable airflow limitation or airway hyperresponsiveness.
CT/HRCT is reserved for selected patients to exclude structural disease. IL-25, β-HB, MUC5AC/CCL17, CaNO, and MRI-DWI are emerging or research markers rather than routine diagnostic criteria. ↑ indicates increased or elevated; ↓ indicates decreased or reduced.Flowchart of CVA diagnosis process including clinical suspicion, tests and imaging.Abbreviations: BHR, bronchial hyperresponsiveness; CaNO, alveolar nitric oxide concentration; CT, computed tomography; CVA, cough variant asthma; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; HRCT, high-resolution computed tomography; MMEF, maximal mid-expiratory flow; MRI-DWI, magnetic resonance imaging diffusion-weighted imaging; PEF, peak expiratory flow; β-HB, β-hydroxybutyrate.
Combining clinical features, pulmonary function indices, and airway inflammatory biomarkers may improve diagnostic accuracy in CVA. In children, FeNO >25 ppb combined with maximal mid-expiratory flow (MMEF) achieved a sensitivity of 75.3% and specificity of 77.6% for identifying CVA.24 Another study reported that cold-triggered cough, exposure to irritant odors, history of allergic rhinitis, and MMEF% were independent predictors, with a combined diagnostic AUC of 0.829.25 These findings suggest that FeNO should be interpreted as an adjunctive biomarker rather than as a standalone diagnostic criterion. In children, lower-airway nitric oxide indices may improve diagnostic discrimination; for example, Zheng et al reported that a CaNO cutoff of 9.45 ppb yielded a sensitivity of 0.816 and a specificity of 0.736.26 In contrast, another study in adults with chronic cough found that FeNO alone had limited predictive value for positive bronchial challenge testing, indicating that its clinical utility is greater when combined with spirometry or bronchial provocation tests.27
Several inflammatory mediators, neuropeptides, and metabolites have been investigated as potential biomarkers of CVA. For Several inflammatory mediators, neuropeptides, and metabolites have been investigated as potential biomarkers of CVA. For instance, a study of 30 patients with CVA showed that IL-25 levels in induced sputum were significantly higher than those in healthy controls and were positively correlated with sputum neutrophil proportions.28 In addition, FeNO levels in patients with CVA were higher than those in healthy individuals but lower than those in patients with classic asthma.29 Emerging omics-based approaches have also been used to identify potential biomarkers.
Metabolomic studies suggest that β-hydroxybutyrate (β-HB) may be associated with disease activity, and experimental data indicate that modulation of β-HB levels may influence cough frequency and inflammatory pathways, including NLRP3 inflammasome activation.30 Proteomic analyses of induced sputum have identified multiple differentially expressed proteins, including MUC5AC and CCL17, although their clinical applicability remains to be established.31
Imaging studies are mainly used to exclude alternative diagnoses rather than to confirm CVA. Conventional chest CT is often normal in patients with CVA, even in those with a positive bronchial provocation test,32 indicating limited diagnostic specificity. However, high-resolution CT may reveal airway wall thickening or mucus plugging in some patients.1 Therefore, imaging should be regarded as an auxiliary tool for differential diagnosis and assessment of airway structural changes, rather than as a primary diagnostic method for CVA.
Genetics
Genetic susceptibility may contribute to the development of CVA, although the available evidence remains less extensive than that for classic asthma. Current studies suggest that CVA shares several asthma-related genetic backgrounds, but it may also show subtype-specific differences in inflammatory pattern, cough sensitivity, and treatment response. Therefore, genetic findings in CVA should be interpreted together with clinical phenotype, airway inflammation, and environmental exposure.
Several candidate gene studies have identified polymorphisms associated with CVA susceptibility and eosinophilic inflammation. In Korean children, rs7216389, rs4794820, and rs4065275 polymorphisms at the GSDMB/ORMDL3 locus were significantly associated with CVA susceptibility, and carriers of risk alleles showed higher sputum eosinophil proportions than non-carriers.33 Another study reported that the CC genotype at the LPCAT1-rs8352 locus was associated with increased susceptibility to CVA in children, accompanied by higher blood eosinophil counts and eosinophil cationic protein (ECP) levels than those observed in patients carrying the GC/GG genotypes.34 These findings suggest that asthma-related susceptibility loci may also participate in CVA development, particularly through eosinophil-associated inflammatory pathways.
In addition to single-gene polymorphisms, transcriptomic studies further indicate molecular heterogeneity among patients with CVA. Cluster analysis of 342 patients with CVA identified distinct clinical and molecular subgroups. In the subgroup characterized by younger age, atopy, and Th2-high inflammation, IL-4 and IL-13 expression levels were significantly higher than those in subgroups characterized by female predominance with late onset and relatively normal lung function, or obesity with longer disease duration and family history.35 Notably, patients in the Th2-high subgroup showed a higher response rate to inhaled corticosteroids (ICS), suggesting that molecular classification may help explain differences in treatment response.35 Consistently, gene expression analysis of peripheral blood mononuclear cells showed increased expression of FCER1A, HDC, and IL4 in patients with CVA compared with healthy controls, further supporting the involvement of IgE-related and Th2-associated pathways in at least part of the CVA population.36
Genetic susceptibility may also interact with environmental exposure in CVA development. A study in inner-city children showed that carriers of the IL4R rs1805015 allele had a higher risk of asthma-related symptoms during school endotoxin exposure.37 Another study reported that the interaction between the IL6 rs2069825 G allele and smoking was associated with increased disease risk and a faster decline in FEV1.38 Although these studies are not all specific to CVA, they support the broader concept that host genetic background may modify the respiratory effects of environmental exposure. This is relevant to CVA because many patients show cough aggravation after exposure to allergens, air pollution, tobacco smoke, cold air, or occupational irritants.
Epigenetic regulation may provide another link between environmental exposure and airway inflammation. In an ovalbumin-sensitized CVA model, TRAP exposure reduced methylation of the IL-4 promoter region and increased IL-4 mRNA expression, suggesting that environmental stimulation may enhance Th2-related airway inflammation through epigenetic mechanisms.13 Maternal smoking during pregnancy has also been associated with altered DNA methylation patterns in fetal lung tissue, which may increase susceptibility to asthma-related airway disease in offspring.39 These findings indicate that genetic predisposition and environmental exposure may not act independently, but may jointly influence immune regulation and airway responsiveness.
Familial aggregation further supports a hereditary component in CVA, although the magnitude of heritability appears lower than that reported for classic asthma. A Japanese family-based study reported a higher occurrence of CVA among first-degree relatives of affected patients than in the general population, but the familial clustering was weaker than that observed in classic asthma.11 Similarly, a Chinese study found that patients with CVA and a family history of asthma had higher sputum eosinophil proportions and FeNO levels than those without such a history.35 These observations suggest that familial background may be associated not only with disease susceptibility, but also with airway inflammatory characteristics.
Overall, current genetic evidence indicates that CVA is related to asthma-associated susceptibility genes, Th2-skewed immune responses, gene–environment interactions, epigenetic regulation, and familial aggregation. However, most available studies are limited by sample size, population specificity, and incomplete phenotype stratification. Future studies should integrate genomic, transcriptomic, epigenetic, environmental, and clinical data to clarify whether distinct genetic backgrounds correspond to specific CVA phenotypes, inflammatory patterns, and treatment responses.
Pathophysiological Basis
Mechanism of Airway Inflammation in CVA
Airway inflammation is an important pathological feature of CVA, but its inflammatory pattern is not completely identical to that of classic asthma (Figure 3). Eosinophilic inflammation is frequently observed in CVA, although its severity and consistency vary among patients. In a study of 116 patients with subacute cough following acute upper respiratory tract infection, sputum eosinophilia was identified in 33.6% of patients, and 14.3% of those with bronchial hyperresponsiveness (BHR) were diagnosed with CVA.
The median sputum eosinophil count in patients with CVA was higher than that in patients with non-asthmatic eosinophilic bronchitis or simple postinfectious cough.40 However, eosinophilic inflammation in CVA is generally less pronounced than that in classic asthma. In a comparative study of 72 patients with CVA and 84 patients with asthma, sputum eosinophil proportions were lower in the CVA group than in patients with moderate classic asthma, and nearly 40% of patients with CVA did not show obvious sputum eosinophilia.40 These findings indicate that CVA is not a uniform eosinophilic disorder. Figure 3Pathophysiological mechanisms of CVA.
The pathogenesis of CVA involves complex and interconnected mechanisms, including airway inflammation, immune imbalance, neurogenic inflammation, and airway remodeling. Airway inflammation is characterized by eosinophilic infiltration, increased type 2 cytokines including interleukin IL-4, IL-5, and IL-13, elevated FeNO, and epithelial irritation. Immune imbalance involves Th2-skewed responses, dysregulation of the Th1/Th2 and Th17/Treg axes, activation of the TLR4/MyD88/NF-κB signaling pathway, and involvement of IL-25.
Neurogenic inflammation and cough hypersensitivity are associated with increased release of CGRP and NGF, enhanced cough reflex sensitivity, and upregulation of TRPA1, TRPV1, and TRPV5. Airway remodeling involves TGF-β1 activation, increased α-SMA, an imbalance between MMP-9 and TIMP-1, collagen deposition, and airway wall thickening. These mechanisms are not mutually exclusive but may interact to sustain airway hyperresponsiveness and chronic cough in CVA.Infographic with a central circle titled Pathophysiological mechanisms of CVA, surrounded by a ring split into four labeled segments.
Each segment points to a colored panel with bullet lists and small icons: a pink panel for airway inflammation (cell and bubble icons), a blue panel for immune imbalance (immune-cell icon), a yellow panel for neurogenic inflammation (neuron icon) and a green panel for airway remodeling (airway cross-section icon). The layout emphasizes four interacting categories rather than a linear pathway.Four-quadrant infographic linking cough-variant asthma to inflammation, immunity, nerves and airway changes.Abbreviations: CVA, cough variant asthma; IL, interleukin; FeNO, fractional exhaled nitric oxide; Th, T helper; Treg, regulatory T cell; TLR4, Toll-like receptor 4; MyD88, myeloid differentiation primary response 88; NF-κB, nuclear factor-κB; CGRP, calcitonin gene-related peptide; NGF, nerve growth factor; TRPA1, transient receptor potential ankyrin 1; TRPV1, transient receptor potential vanilloid 1; TRPV5, transient receptor potential vanilloid 5; TGF-β1, transforming growth factor-β1; α-SMA, α-smooth muscle actin; MMP-9, matrix metalloproteinase-9; TIMP-1, tissue inhibitor of metalloproteinases-1.
BHR in CVA may also occur independently of marked eosinophilic inflammation. Moderate BHR has been reported in approximately 60% of patients with CVA without sputum eosinophilia,41 suggesting that non-eosinophilic inflammatory processes, epithelial irritation, and neural mechanisms may also contribute to cough persistence. Therefore, airway inflammation in CVA should be understood as a heterogeneous process involving both eosinophilic and non-eosinophilic components.
Environmental exposure may further aggravate airway inflammation and cough hypersensitivity in CVA. In a guinea pig model, TRAP exposure increased citric acid-induced cough responses and was associated with an eosinophil proportion of approximately 30% in BALF after 7–14 days of exposure.13 Glucocorticoid treatment attenuated this inflammatory response, supporting the role of airway inflammation in pollutant-induced cough hypersensitivity.13 In addition, irritant stimulation may activate airway sensory pathways. The upregulation of transient receptor potential channels, including TRPA1, TRPV1, and TRPV5, has been associated with increased release of neuropeptides such as calcitonin gene-related peptide (CGRP) and nerve growth factor (NGF), which may enhance cough reflex sensitivity.42
Taken together, airway inflammation in CVA involves eosinophilic inflammation, variable BHR, environmental irritation, and neurogenic inflammatory pathways. This heterogeneity may partly explain why some patients respond well to anti-inflammatory therapy, whereas others continue to experience persistent cough despite relatively mild eosinophilic inflammation.
Potential TCM-Syndrome Correlates
Heterogeneous inflammatory patterns observed in CVA may tentatively correspond to distinct TCM syndrome patterns, although direct human evidence remains limited and these associations represent hypothetical correlations rather than one-to-one biological equivalence. The wind-cold pattern, characterized by cough triggered by cold air and irritants, is clinically speculated to overlap with Th2-eosinophilic inflammation and cough-hypersensitivity phenotypes. Patients presenting with the phlegm-heat pattern, manifested by yellowish sputum, throat heat sensation and aggravated cough upon heat exposure, may show higher neutrophilic airway inflammation.
At present, few prospective studies have systematically tested these relationships; further studies correlating sputum cellular profiles, FeNO and other biomarkers with standardized TCM syndrome differentiation are required to validate these preliminary observational hypotheses.
Immunological Characteristics of CVA
Immune imbalance is an important feature of CVA and is closely related to airway inflammation, cough hypersensitivity, and bronchial hyperresponsiveness. Similar to classic asthma, CVA is often associated with Th2-skewed inflammation, although the degree and pattern of immune activation may differ among patients. A study involving 38 patients with asthma, including 13 patients with CVA, showed that interleukin-25 (IL-25) levels in induced sputum were lower in CVA than in severe typical asthma but higher than in healthy controls.
IL-25 levels were also positively correlated with sputum neutrophil proportions, suggesting that IL-25 may participate in neutrophil-associated airway inflammation in CVA.28
In addition to Th2-related responses, other immune pathways may contribute to the inflammatory profile of CVA. Experimental studies have suggested that the TLR4/MyD88/NF-κB pathway may regulate inflammatory cytokine production in CVA models. In a rat model of CVA, reduced levels of interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) in BALF were accompanied by downregulation of TLR4, MyD88, and phosphorylated NF-κB p65, as well as increased interferon-γ (IFN-γ) levels.43 These findings indicate that both pro-inflammatory signaling and Th1/Th2 immune balance may be involved in CVA-related airway inflammation.
Peripheral immune-cell analyses further support the involvement of T-cell imbalance in CVA. In peripheral blood mononuclear cells from patients with CVA, CD4+ T cells showed a shift toward a Th2 phenotype, with a higher proportion of IL-4+CD4+ T cells than in healthy controls.44 In an ovalbumin-induced CVA guinea pig model, changes in Th2-related cytokines, including IL-4, IL-5, and IL-13, were associated with airway inflammation and increased airway resistance.44 Taken together, current evidence suggests that CVA involves a heterogeneous immune profile characterized by Th2-skewed inflammation, variable neutrophil-associated responses, inflammatory cytokine activation, and altered Th1/Th2 balance.
Potential TCM-Syndrome Correlates
Dysregulated T-cell immune axes in CVA provide a potential biological background for TCM syndrome stratification. Predominant Th2-skewed immune responses are frequently observed in patients with wind-exogenous and wind-cold patterns, whereas mixed Th17/neutrophil-dominant inflammatory profiles are more often reported in patients assigned to phlegm-heat syndrome. Deficiency-type syndromes (lung-spleen qi deficiency) tend to present with poorer immune homeostasis and higher recurrence risk after treatment discontinuation.
It should be emphasized that existing data mostly derive from small-sized single-center observational cohorts. No unified syndrome-biomarker mapping standard has been established, and confounders such as disease duration, age and medication history cannot be fully excluded. Large-scale prospective studies integrating standardized TCM diagnosis and immunological readouts are urgently needed.
Airway Remodeling in CVA
Airway remodeling in CVA is generally milder than that in typical asthma, but structural airway changes may still occur and contribute to persistent airflow limitation in some patients. In a study of 459 patients, airway wall collagen deposition in CVA was lower than that in typical asthma but higher than that in healthy controls, suggesting that remodeling can be present even in early or less severe asthma-related disease.45
Transforming growth factor-β1 (TGF-β1) is an important mediator of airway remodeling. Experimental studies indicate that increased TGF-β1 expression is associated with airway smooth muscle proliferation, collagen deposition, and increased airway resistance in CVA models.46 NF-κB signaling may also participate in airway inflammation and remodeling, partly through its interaction with TGF-β1-related pathways.47 These findings suggest that inflammatory signaling and remodeling pathways are closely linked in CVA.
Persistent cough may further contribute to airway remodeling through repeated mechanical stress. A retrospective study found that patients with cough lasting more than 12 months had greater airway wall collagen deposition than those with a shorter disease duration.48 Early anti-inflammatory treatment may help reduce progression risk. In a follow-up study of 42 patients, early use of inhaled corticosteroids was associated with a lower rate of progression to typical asthma over four years compared with non-use.49
Some experimental studies have also suggested that TCM interventions may influence airway remodeling-related pathways. For example, Eriobotrya japonica leaf extract reduced airway smooth muscle α-SMA expression and improved lung function in a CVA model, possibly through modulation of the intestinal microbiota and inhibition of the MMP-9/TIMP-1 pathway.50 However, this evidence remains mainly experimental, and further clinical studies are needed to determine whether these remodeling-related effects translate into long-term benefits in patients with CVA.
Potential TCM-Syndrome Correlates
Progressive airway structural changes are clinically linked to the blood-stasis syndrome in TCM theory, which is commonly seen in long-standing, recurrent CVA. Patients with prolonged disease duration who meet TCM blood-stasis criteria may exhibit more prominent collagen deposition and worse long-term pulmonary function trajectories. Meanwhile, combined lung-spleen-kidney deficiency is hypothesized to increase susceptibility to persistent remodeling by impairing host reparative capacity.
Current evidence is indirect; dedicated clinical studies evaluating imaging-derived airway-remodeling indices against TCM syndrome classifications are lacking.
Treatment
The pharmacological management of CVA is mainly based on asthma-directed therapy, particularly inhaled corticosteroids (ICS), with bronchodilators or leukotriene receptor antagonists used according to clinical features and treatment response. In a study of 43 patients with CVA, combination therapy with ICS and a long-acting β2-agonist (LABA) improved cough score, FEV1, and sputum eosinophil proportion after 12 weeks.51 Leukotriene receptor antagonists may also be beneficial in selected patients. In a study involving 23 patients with CVA, four weeks of montelukast treatment improved cough visual analog scale (VAS) scores and capsaicin cough threshold.52
TCM has also been explored as an adjunctive approach for CVA, particularly in relation to cough relief, airway inflammation, and immune regulation. In experimental models, Suhuang antitussive capsules reduced interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) levels in BALF, which was associated with inhibition of the TLR4/NF-κB signaling pathway.43 Another experimental study reported that emodin reduced IgE levels and alleviated airway inflammation in a CVA mouse model through modulation of the Notch signaling pathway.52 These findings provide mechanistic support for the potential adjunctive role of TCM, although clinical validation remains necessary.
Nonpharmacological management is also important, especially for patients with identifiable triggers or prominent cough hypersensitivity. Avoidance of known triggers, such as cold air and irritant odors, has been associated with improvement in cough symptom scores.25 Psychological factors may also influence symptom burden. One study reported higher levels of anxiety and depression in patients with CVA than in those with typical asthma, and psychological intervention was associated with a reduction in cough symptom scores.53 Rehabilitation training may be considered as supportive care for selected patients, but direct evidence in CVA remains limited.
Therefore, its role should be further evaluated in disease-specific studies rather than extrapolated only from other chronic conditions.
Treatment selection may be improved by considering clinical phenotypes and relevant biomarkers. Cluster analysis has identified distinct CVA subtypes; for example, patients characterized by younger age, atopy, and Th2-high inflammation showed a higher response rate to ICS than other clusters.35 FeNO may also assist in treatment selection, as patients with FeNO >25 ppb have been reported to show greater response to ICS than those with lower FeNO levels.24 These findings suggest that phenotype- and biomarker-guided treatment may help improve individualized management of CVA.
Combination strategies may be useful when CVA coexists with other treatable conditions or when symptom control remains incomplete. In a patient with CVA and GERD, combined treatment with ICS/LABA and a proton pump inhibitor (PPI) was associated with complete resolution of cough symptoms after six weeks and a decrease in FeNO from 35 ppb to 15 ppb.54 Integrative treatment combining TCM with conventional therapy has also been investigated. For example, Suhuang antitussive capsules combined with ICS showed a higher overall response rate than ICS alone.55 Such combined approaches may reflect complementary therapeutic effects, with conventional therapies targeting airway inflammation and bronchial reactivity, and TCM potentially contributing to multi-pathway regulation.
The Basic Theory of CVA in Traditional Chinese Medicine
In TCM, CVA is generally discussed with reference to the traditional concepts of “cough” and “asthma,” although it is more closely related to “cough” because persistent or recurrent cough is the predominant manifestation, whereas wheezing and obvious dyspnea are usually absent. TCM theory interprets CVA as a disorder involving external triggers, impaired regulation of lung qi, phlegm retention, blood stasis, and functional deficiency of the lung, spleen, and kidney systems. In this context, external triggers refer to factors such as cold air, allergens, irritant odors, or respiratory infection; impaired lung qi regulation refers to disturbed respiratory movement manifesting as recurrent cough; phlegm retention refers to abnormal fluid metabolism and airway obstruction; blood stasis refers to impaired circulation of qi and blood in prolonged disease; and deficiency of the lung, spleen, and kidney systems refers to weakened regulation of respiratory defense, fluid metabolism, and respiratory stability.
This interpretation is consistent with the clinical feature that CVA often presents as chronic or recurrent cough triggered by external stimulation.1
In TCM theory, “wind” is used as a traditional explanatory term for cough with sudden onset, fluctuation, recurrence, and sensitivity to external stimulation, rather than as a literal pathogenic entity. In the context of CVA, this concept is mainly used to describe cough that is easily induced by cold air, seasonal change, allergens, smoke, or irritating odors. These features are broadly consistent with the clinical observation that patients with CVA often show cough hypersensitivity and airway hyperresponsiveness.1,27 Therefore, in this review, wind-related terminology is used mainly to describe the trigger-sensitive and fluctuating nature of cough, rather than to imply a direct biomedical mechanism.
Phlegm and blood stasis are also frequently used in TCM explanations of chronic or recurrent cough. In this context, phlegm refers not only to visible sputum, but also to a broader TCM concept of abnormal fluid metabolism and airway obstruction, which may clinically correspond to throat irritation, sticky sputum, mucus-related discomfort, or a sensation of airway blockage. Blood stasis refers to impaired circulation of qi and blood in TCM theory and is usually used to explain prolonged disease, recurrent symptoms, or poor resolution after repeated episodes.
These concepts should not be regarded as direct equivalents of mucus secretion, vascular dysfunction, or inflammation, but they provide a traditional framework for explaining why some patients experience persistent or relapsing cough.
The lung, spleen and kidney systems are considered important internal factors in the recurrence of CVA. Lung deficiency refers to weakened respiratory defense and reduced tolerance to external stimulation. Spleen deficiency refers to impaired fluid metabolism, which is believed to promote dampness and phlegm formation.
Kidney deficiency refers to reduced support for respiratory stability, especially in patients with long disease duration, recurrent attacks, or constitutional weakness. In this framework, CVA is not viewed as a purely acute cough condition, but as a recurrent disorder in which external triggers act on a susceptible internal state.
Syndrome differentiation is the main method used to classify CVA in TCM practice. Instead of grouping patients only according to the biomedical diagnosis of CVA, TCM further classifies patients according to cough pattern, triggering factors, sputum characteristics, accompanying symptoms, tongue appearance and pulse condition.56 Commonly described patterns include externally triggered cough, cold-sensitive cough, heat-associated cough, phlegm-related cough, lung qi deficiency, spleen qi deficiency, lung-yin deficiency, and kidney-related deficiency. For example, cough that is aggravated by cold air may be interpreted as a cold-sensitive pattern, whereas recurrent cough with fatigue, spontaneous sweating, and susceptibility to respiratory infection may suggest lung qi deficiency.
This classification provides the basis for individualized treatment selection in TCM.
Accordingly, the therapeutic principles of TCM for CVA are based on both symptom control and recurrence prevention. During periods of active cough, treatment generally focuses on reducing cough sensitivity, improving the regulation of lung qi, and addressing associated features such as cold sensitivity, heat signs, throat irritation, or phlegm-related symptoms.57 During remission or recurrent stages, treatment places greater emphasis on improving the patient’s underlying susceptibility, including strengthening lung function, improving spleen-related fluid regulation, nourishing yin when dryness is prominent, and supporting kidney-related respiratory stability in chronic or recurrent cases. Therefore, the TCM approach is not limited to temporary cough suppression but aims to match treatment principles with the patient’s overall syndrome pattern.
Although TCM and modern medicine use different conceptual systems, some TCM concepts can be cautiously linked with recognized clinical and biological features of CVA. For example, externally triggered cough may be discussed in relation to environmental exposure, airway irritation, and cough hypersensitivity; phlegm-related patterns may be discussed in relation to mucus secretion and airway inflammation; and deficiency-related patterns may be considered in relation to recurrent airway inflammation, impaired host defense, and variable response to treatment. Current studies indicate that CVA involves airway inflammation, airway hyperresponsiveness, cough hypersensitivity, and heterogeneous responses to anti-asthmatic therapy.1,27 However, these links should be interpreted as explanatory associations rather than direct equivalence between TCM syndromes and molecular mechanisms.
The traditional relationship between the lung, spleen, kidney and large intestine also provides a theoretical basis for understanding CVA from a systemic perspective. In TCM, the lung–spleen relationship is used to explain the connection between respiratory symptoms and fluid metabolism, the lung–kidney relationship is used to explain chronicity and respiratory stability, and the lung–large intestine relationship is used to explain the interaction between respiratory and digestive functions. Recent asthma studies suggest that gut microbiota and microbial metabolites may influence airway inflammation and immune regulation through the gut–lung axis, which provides a possible biomedical context for discussing the traditional lung–large intestine relationship.58,59 Nevertheless, direct evidence in CVA remains limited, and this relationship should be discussed cautiously.
Overall, this section clarifies the TCM theoretical basis of CVA, including disease attribution, trigger sensitivity, internal susceptibility, phlegm- and stasis-related explanations, syndrome differentiation, and general treatment principles. The detailed herbal prescriptions, experimental mechanisms, signaling pathways, and clinical efficacy data are discussed in the following sections to maintain a clearer distinction between TCM theory, mechanistic evidence, and clinical application.
Analysis of the Current Situation of CVA in Traditional Chinese Medicine
In recent years, TCM-related research on CVA has gradually expanded from empirical symptom-based treatment to a more structured evaluation of clinical efficacy, syndrome differentiation, prescription characteristics, and possible biological mechanisms. However, the current evidence remains heterogeneous. Some studies focus on Chinese patent medicines or classical prescriptions, whereas others examine acupuncture, external application, or individualized herbal treatment.
Therefore, when discussing the current status of TCM in CVA, it is necessary to distinguish between guideline or consensus evidence, clinical trial evidence, and exploratory mechanistic evidence.
At present, available consensus and guideline-related documents mainly support the standardized use of selected TCM interventions in respiratory diseases and cough-related conditions. Among Chinese patent medicines, Suhuang Zhike Capsules have been specifically addressed in an expert consensus, which summarizes their indications, applicable TCM syndrome features, usage, contraindications, and safety considerations in respiratory diseases, including CVA.60 This formulation-specific consensus provides guidance for the clinical use of Suhuang Zhike Capsules, whereas broader CVA management still requires more standardized evidence across different TCM interventions.
Clinical evidence on herbal medicine for CVA has also increased. A systematic review and meta-analysis of adult patients with CVA suggested that herbal medicine may improve cough-related symptoms and quality of life compared with conventional treatment alone, but the included trials varied in intervention composition, treatment duration, and outcome assessment.61 In children with CVA, a systematic review of traditional Chinese herbs reported potential benefits in clinical response and symptom improvement, although the included studies differed in methodological quality and treatment protocols.62 These findings suggest that TCM may have adjunctive value in CVA management, but the conclusions should be interpreted according to the quality and scope of the available clinical evidence.
Research on Chinese patent medicines has provided more formulation-specific evidence. Suhuang Zhike Capsules have been evaluated in systematic reviews and clinical studies, with reported improvements in cough symptoms and safety outcomes in patients with CVA.63,64 A recent Phase IV real-world clinical study also reported the efficacy and safety of Suhuang Zhike Capsules in CVA, providing additional clinical data from routine practice.64 Nevertheless, real-world evidence and meta-analytic findings should be considered complementary to, rather than a replacement for, large randomized controlled trials with standardized diagnostic criteria and predefined outcomes.
Mechanistic studies have mainly focused on immune regulation, airway inflammation, airway hyperresponsiveness, airway remodeling, and the gut–lung axis. In addition, network pharmacology and omics-based approaches have been used to explore potential active components and molecular targets of herbal prescriptions. These studies help explain the biological plausibility of multi-component TCM interventions in CVA, although many predicted targets and pathways still require experimental and clinical validation.65 Therefore, mechanistic evidence should be used to support biological plausibility, not to overstate proven clinical efficacy.
Overall, the current status of TCM in CVA can be summarized as follows: clinical application is active, formulation-specific evidence is accumulating, and mechanistic research is developing rapidly, but the level of evidence remains heterogeneous. Future studies should focus on consistent diagnostic criteria, standardized syndrome classification, reproducible intervention protocols, objective outcome measures, and multicenter randomized controlled trials. Such work will help clarify which patient groups are most likely to benefit from TCM-based interventions and how these interventions can be integrated with conventional CVA management.
Clinical Practice of CVA in Traditional Chinese Medicine
The clinical efficacy of TCM for CVA has been evaluated in several randomized controlled trials (RCTs). A meta-analysis of 20 randomized controlled trials reported a pooled total effective rate of approximately 92.3% for TCM-based interventions, with a reduction in recurrence compared to control groups; however, significant heterogeneity and potential publication bias should be considered when interpreting these findings.66 In adult patients, Suhuang Zhike capsule monotherapy was associated with a total effective rate of 90.57%, with a decrease in cough symptom score from 12.5 to 4.2.67 In children, the combination of TCM with routine treatment has been reported to reduce IgE levels by 28.9% and decrease PEF variability from 25.3% to 18.7%.62
Clinical and experimental studies suggest that TCM-based interventions may improve CVA symptoms through several related processes, including modulation of airway inflammation, regulation of immune imbalance, and reduction of airway hyperresponsiveness. In addition to oral herbal treatment, acupuncture and external application therapies have also been explored as adjunctive approaches in CVA management. Existing studies indicate that acupuncture-related interventions may contribute to cough relief and improvement in pulmonary function indices, while external herbal application may influence immune-related indicators such as the IFN-γ/IL-4 balance.66 Improvements in patient-reported outcomes have also been reported, including increased Leicester Cough Questionnaire (LCQ) scores in patients receiving TCM-based treatment.62 However, differences in intervention protocols, treatment duration, comparator selection, and outcome assessment still limit the strength and comparability of the available evidence.
Individualized treatment is a key feature of TCM practice and is based on syndrome differentiation and constitutional assessment. Clinical data indicate that common syndrome patterns in asthma-related conditions include wind-related lung patterns, phlegm-heat accumulation, lung-qi and spleen-qi deficiency, and lung-yin or kidney-yin deficiency.68 In CVA, syndrome differentiation is mainly used to guide treatment selection according to cough characteristics, inducing factors, sputum features, accompanying symptoms, and constitutional status. For example, Shufeng Zhike formulations have been used for wind-related cough patterns and have been associated with improvement in cough symptoms.67 For phlegm-heat, qi-deficiency, or yin-deficiency patterns, treatment is usually adjusted by selecting herbs with phlegm-resolving, qi-tonifying, or yin-nourishing properties according to the patient’s dominant clinical presentation.69 This individualized approach reflects the clinical logic of TCM treatment, although further standardized studies are still needed to clarify the reproducibility of syndrome-based prescriptions in CVA.
The treatment strategies may differ across specific patient groups. In children, modified Sangju Yin and related prescriptions have been used, with reported efficacy rates of 89.7%.62 In older patients with features of kidney deficiency, therapies including Psoralea corylifolia and walnut kernel have been associated with a reduction in nocturnal cough frequency.67 In patients with CVA and gastroesophageal reflux, combined treatment with Xuanfu Daizhe Decoction and Zhisou Powder has been reported to improve both reflux symptoms and cough severity.70
The safety of TCM interventions for CVA has been assessed in several clinical studies and systematic reviews. A meta-analysis of the Suhuang Zhike capsule reported an adverse event rate of 3.2%, mainly involving mild gastrointestinal discomfort and dizziness.63 A systematic review found that the incidence of adverse reactions in TCM adjunctive therapy was 4.1% compared with 12.3% in the control group.66 In children, adverse events occurred in 2.7% of cases and were mostly mild and reversible.62
Available follow-up data in current literture have not shown clear evidence of liver or kidney injury related to TCM treatment for CVA, although long-term safety evidence remains limited. For instance, a 6-month follow-up study showed no significant differences in liver or kidney function (ALT, AST, Scr) between the treatment and control groups.7 In addition, some herbal combinations may reduce drug-related side effects; for example, the combination of ephedra and licorice has been reported to lower the incidence of palpitations associated with ephedrine.69
Despite these findings, several limitations should be considered. Many studies have been limited by small sample sizes, short follow-up durations, and differences in outcome measures, which may affect the reliability and generalizability of the results. In addition, the variability in herbal formulations and syndrome classification makes standardization difficult.
Therefore, while TCM may serve as a complementary approach in the management of CVA, further high-quality, multicenter, randomized controlled trials with standardized protocols are needed to clarify its clinical value. (See Figure 4). Figure 4Integrative mapping of TCM theory, modern biological mechanisms, and therapeutic strategies in CVA.
This figure summarizes the conceptual links between major TCM pathogenic patterns in CVA and selected modern pathophysiological mechanisms, together with representative TCM therapeutic principles and commonly used prescriptions. On the left, the main TCM concepts include exogenous wind invasion, impaired regulation of lung qi, phlegm and blood stasis, and spleen and kidney deficiency. In the middle, these patterns are related to three major biological modules: inflammatory responses, including activation of the TLR4/NF-κB and IL-6/STAT3 pathways, increased IL-1β and TNF-α, and modulation of the Notch pathway; immune dysregulation, including Th17/Treg imbalance and IL-17 activation; and airway remodeling, including MMP-9/TIMP-1 imbalance, increased α-SMA expression, smooth muscle proliferation, and collagen deposition.
On the right, representative therapeutic strategies are shown, including dispelling wind and relieving cough, ventilating lung qi; resolving phlegm and blood stasis, and clearing heat and inflammation; and tonifying the lung, strengthening the spleen, and nourishing the kidney, together with example prescriptions such as Ephedra-Apricot Kernel-Mulberry Leaf-Chrysanthemum, Xiaoqinglong Decoction, Suhuang Zhike Capsule, Baihe Gujin Decoction, and Maxingshigan Decoction. The connecting arrows indicate a conceptual correspondence between TCM syndrome-based interpretation, modern mechanistic understanding, and therapeutic translation, rather than direct one-to-one equivalence.Three-column flowchart connecting TCM syndromes to airway biology and example herbal formulas.Abbreviations: CVA, cough variant asthma; TCM, traditional Chinese medicine; TLR4, Toll-like receptor 4; NF-κB, nuclear factor-κB; IL, interleukin; STAT3, signal transducer and activator of transcription 3; TNF-α, tumor necrosis factor-α; Th17, T helper 17 cell; Treg, regulatory T cell; MMP-9, matrix metalloproteinase-9; TIMP-1, tissue inhibitor of metalloproteinases-1; α-SMA, α-smooth muscle actin.
Future Perspectives
Future research on TCM for CVA should focus on patient stratification, mechanistic validation, and higher-quality clinical evidence (Figure 5). Classification based on clinical features, inflammatory phenotypes, biomarkers, and TCM syndrome patterns may help identify patients who are more likely to benefit from specific interventions, although this approach still requires validation in prospective studies.65 Further research is also needed to clarify the relationship among intestinal microbiota, immune responses, airway inflammation, and cough hypersensitivity, which may help explain the multi-target effects of TCM in CVA.50 In clinical research, large multicenter randomized controlled trials with standardized diagnostic criteria, clearly defined intervention protocols, and consistent outcome measures are needed to improve the reliability and comparability of evidence.55Figure 5Future directions for the development and clinical translation of TCM in CVA. The future development of TCM for CVA may proceed along four complementary directions.
Precision treatment emphasizes patient stratification and individualized TCM selection based on clinical phenotypes, syndrome patterns, biomarkers, and potentially genetic polymorphisms. Mechanistic exploration focuses on clarifying the gut microbiota–immune–airway axis and validating the multi-target mechanisms underlying TCM interventions. Drug and technology innovation includes the application of AI-based compound screening and emerging experimental platforms, such as microfluidic chip models, to improve active-compound identification, target discovery, and mechanistic validation.
Evidence-based development and globalization require standardized diagnostic and syndrome-classification criteria, high-quality multicenter clinical trials, harmonized outcome measures, international guideline evaluation, and appropriate regulatory pathways for wider global registration and implementation. Collectively, these directions aim to facilitate the transition of TCM for CVA from empirical and exploratory use toward more precise, mechanism-informed, evidence-based, and internationally standardized clinical application.Infographic on future directions of TCM in CVA with four focus areas.Abbreviations: TCM, traditional Chinese medicine; CVA, cough variant asthma; AI, artificial intelligence.
New research methods may also support the development of TCM-based interventions for CVA. Artificial intelligence has been used to screen herbal combinations, and experimental platforms such as microfluidic systems may help improve target identification and mechanism validation.65,71 However, these approaches remain exploratory and should be validated through experimental and clinical studies before routine application. Combining TCM with modern therapies, including biological agents, may also be a future direction, but current evidence remains insufficient to support firm conclusions regarding its clinical value.
The international application of TCM for CVA remains at an early stage. Current efforts mainly focus on standardizing syndrome differentiation, improving outcome evaluation, and aligning TCM research with broader clinical evidence frameworks.65 Some TCM products, such as Suhuang Zhike Capsules, have been introduced in certain regions outside China. However, wider application will depend on stronger clinical evidence, clearer regulatory pathways, improved formulation standardization, and more transparent reporting of efficacy and safety outcomes.63
Conclusion
In summary, accumulating evidence indicates that TCM represents a promising complementary strategy for CVA management, with biological plausibility supported by pre-clinical data pointing to modulatory effects on airway inflammation, immune dysregulation, airway remodeling, the TLR4/NF-κB, Th2-related cytokine networks, PI3K/AKT pathways, and the gut-lung axis. Nevertheless, clinical evidence remains constrained by methodological heterogeneity, non-standardized diagnostic and syndrome-classification criteria, inconsistent outcome metrics, and over-reliance on preclinical mechanistic findings. Interpretations of reported TCM therapeutic efficacy must therefore account for study quality and trial design.
This review highlights three core unresolved bottlenecks hindering the clinical translation of TCM for CVA: establishing biologically grounded standards for TCM syndrome differentiation; identifying patient subgroups most likely to benefit from TCM interventions; and developing trial methodologies compatible with both holistic TCM logic and international regulatory research standards. From a translational standpoint, pragmatic trials embedding patient-reported outcomes alongside implementation-science frameworks are recommended to generate real-world evidence supporting integration of TCM into routine CVA care pathways. Further work should clarify differential treatment responses according to inflammatory phenotypes and TCM syndromes.
Standardized treatment protocols, objective endpoints, multicenter trials, and mechanism-driven validation remain essential to strengthen evidence and define the place of integrative TCM within global respiratory practice.